Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11159367 | 0.77 | MEN1 (0.42) | KMT2AMEN1NPC1RAB9AMTNR1A | |
| SCHEMBL6724764 | 0.77 | MEN1 (0.42) | KMT2AMEN1NPC1RAB9AMTNR1A | |
| Hydrochloric Acid SCHEMBL11394663 | 0.76 | IDO1 (0.43) | KMT2AALDH1A1MEN1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL11394668 | 0.76 | IDO1 (0.43) | KMT2AALDH1A1MEN1NPC1RAB9A | |
| Bicarbonate SCHEMBL3212051 | 0.75 | KDM4E (0.54) | KMT2AALDH1A1MEN1NPC1RAB9A | |
| SCHEMBL4460773 | 0.75 | HIF1A (0.49) | KMT2AMEN1NPC1RAB9AMTNR1A | |
| SCHEMBL9580083 | 0.75 | ALDH1A1 (0.53) | KMT2AALDH1A1TSHRMEN1HTT | |
| SCHEMBL6826870 | 0.74 | KMT2A (0.42) | KMT2AALDH1A1TSHRTAAR1 | |
| SCHEMBL444608 | 0.74 | ALDH1A1 (0.57) | KMT2AALDH1A1TSHRMEN1NPC1 | |
| SCHEMBL1133249 | 0.73 | BLM (0.46) | KMT2AALDH1A1MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957016-B2 | Tumor activated prodrugs | GENSPERA, INC. | 2015-02-17 | — | — | US | disclosed |
| US-8822406-B2 | Tumor activated prodrugs | GENSPERA, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8772226-B2 | Methods and compositions for the detection of cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120270768-A1 | Tumor Activated Prodrugs | INSPYR THERAPEUTICS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20120270767-A1 | Tumor Activated Prodrugs | INSPYR THERAPEUTICS, INC. | 2012-10-25 | — | — | US | disclosed |
| US-20120093724-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2408465-A2 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | The Johns Hopkins University (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010107909-A2 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| US-7767648-B2 | Tissue specific prodrugs | GENSPERA, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100120697-A1 | Tumor Activated Prodrugs | GENSPERA, INC. | 2010-05-13 | — | — | US | disclosed |
| WO-2007081516-A2 | TUMOR ACTIVATED PRODRUGS | GENSPERA, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20070160536-A1 | prodrug comprising 8-O-(12[L-leucinoylamino]dodecanoyl)-8-O-debutanoylthapsigargin (L12ADT); and a peptide of sequence Ser-Ser-Lys-Tyr-Gln; peptide is linked to the L12ADT to inhibit the therapeutic activity of the drug; anticarcinogenic agent; benign prostate hyperplasia; prostate and breast cancer | INSPYR THERAPEUTICS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20040029778-A1 | Tissue specific prodrugs | INSPYR THERAPEUTICS, INC. | 2004-02-12 | — | — | US | disclosed |
| US-6545131-B1 | Splitting drug with prostate specific antigen; activation of drug; antiproliferative agents | THE JOHNS HOPKINS UNIVERSITY | 2003-04-08 | — | — | US | disclosed |
| US-6504014-B1 | Tissue specific prodrug | THE JOHN HOPKINS UNIVERSITY | 2003-01-07 | — | — | US | disclosed |
| US-6410514-B1 | MIXTURE OF THERAPEUTICALLY ACTIVE DRUG AND PEPTIDE | THE JOHNS HOPKINS UNIVERSITY | 2002-06-25 | — | — | US | disclosed |
| WO-2002043773-A2 | TISSUE SPECIFIC PRODRUGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2002-06-06 | — | — | WO | disclosed |
| WO-2001093861-A1 | TISSUE SPECIFIC PRODRUG | THE JOHN HOPKINS UNIVERSITY (US) | 2001-12-13 | — | — | WO | disclosed |
| US-6265540-B1 | PEPTIDE HAVING SPECIFIC AMINO ACID SEQUENCE WHICH IS CLEAVAGE SITE FOR PROSTATE SPECIFIC ANTIGEN PROTEOLYTIC ACTIVITY; ANTIPROLIFERATIVE AGENTS | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2001-07-24 | — | — | US | disclosed |
| WO-1998052966-A1 | TISSUE SPECIFIC PRODRUG | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDECINE (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093724-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | KLK3, KLK2, KLK5 | KMT2A 351/4885ALDH1A1 1673/4885TSHR 4530/4885 |
| US-20120270768-A1 | Tumor Activated Prodrugs | PREP, DNPEP, THOP1 | KMT2A 1241/4885ALDH1A1 1699/4885TSHR 1678/4885 |
| US-20070160536-A1 | prodrug comprising 8-O-(12[L-leucinoylamino]dodecanoyl)-8-O-debutanoylthapsigargin (L12ADT); and a peptide of sequence Ser-Ser-Lys-Tyr-Gln; peptide is linked to the L12ADT to inhibit the therapeutic activity of the drug; anticarcinogenic agent; benign prostate hyperplasia; prostate and breast cancer | PEPD, BPHL, PTMS | KMT2A 129/4885ALDH1A1 1255/4885TSHR 1982/4885 |
| US-20100120697-A1 | Tumor Activated Prodrugs | DNPEP, PREP, PEPD | KMT2A 684/4885ALDH1A1 2136/4885TSHR 3537/4885 |
| US-20120270767-A1 | Tumor Activated Prodrugs | DNPEP, PREP, PEPD | KMT2A 684/4885ALDH1A1 2136/4885TSHR 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.